Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 87 for “"Clinical Development"”.

  1. Decision making in clinical development

    L'abstract è presente nell'allegato / the abstract is in the attachment

    poli-torino Repository record for Decision making in clinical development (opens in a new tab)

  2. The Cape Town Stereotactic pointer clinical development and Applications

    This dissertation describes the development and clinical use of a novel stereotactic neurosurgical system, the Cape Town Stereotactic Pointer (CTSP). This system has four main components; a halo containing three fiducials also serves as the platform for a tripod pointing device which is set with …

    cape-town Repository record for The Cape Town Stereotactic pointer clinical development and Applications (opens in a new tab)

  3. Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development

    … aspects of the value in performing oncology clinical trials using screening biomarkers to preferentially select and enroll responders. From trial reports and investigational reports on potential biomarkers, I construct a series of six cases comparing the trial as conducted to a hypothetical …

    mit Repository record for Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development (opens in a new tab)

  4. Best Practices in a Clinical Development Project Management Office (PMO) to Achieve a Reference Standard in the Pharmaceutical Industry

    … with the discovery phase, proceeds to preclinical trials, moves into clinical trials (progressing from Phase I to Phase III), and if the data are positive, may lead to Food and Drug Administration (FDA) approval. Once approved, post-marketing surveillance for safety is required as long as …

    dominican Repository record for Best Practices in a Clinical Development Project Management Office (PMO) to Achieve a Reference Standard in the Pharmaceutical Industry (opens in a new tab)

  5. Pre-clinical development of cyclodextrin-based nanoparticles for oral delivery of protein/peptide drugs-in vitro and in vivo evaluation

    … as liraglutide. In the first stage of the preclinical development of these formulations, the fabrication process of the three prototypes containing the different cargos was optimized. The resulting formulations showed suitable physico-chemical properties for an oral administration as well as …

    cork Repository record for Pre-clinical development of cyclodextrin-based nanoparticles for oral delivery of protein/peptide drugs-in vitro and in vivo evaluation (opens in a new tab)

  6. Enhertu (Trastuzumab Deruxtecan): Ανασκόπηση της κλινικής ανάπτυξης σε ασθενείς με HER2+ καρκίνο μαστού / Enhertu (Trastuzumab Deruxtecan): A review of clinical development in patients with HER2-positive breast cancer

    … ιστοσελίδες καταχώρησης κλινικών μελετών όπως το ClinicalTrials.gov. Αναλύθηκαν δεδομένα από κλινικές δοκιμές, καταθέσεις κλινικών δοκιμών στις ρυθμιστικές αρχές και κατευθυντήριες οδηγίες διεθνών οργανισμών (ESMO). Επίσης, εξετάστηκαν οι περιλήψεις χαρακτηριστικών του προϊόντος (SmPC) του Enhertu …

    athens Repository record for Enhertu (Trastuzumab Deruxtecan): Ανασκόπηση της κλινικής ανάπτυξης σε ασθενείς με HER2+ καρκίνο μαστού / Enhertu (Trastuzumab Deruxtecan): A review of clinical development in patients with HER2-positive breast cancer (opens in a new tab)

  7. Η προκλινική και κλινική ανάπτυξη του Belantamab Mafodotin για τη θεραπεία του Πολλαπλού Μυελώματος/The preclinical and clinical development of Belantamab Mafodotin for the treatment of Multiple Myeloma

    Το πολλαπλό μυέλωμα αποτελεί μία κακοήθη αιματολογική νόσο των πλασματοκυττάρων, η οποία χαρακτηρίζεται από ετερογενή κλινική εικόνα, σύνθετη παθοφυσιολογία και υψηλά ποσοστά υποτροπής, παρά την πρόοδο των διαθέσιμων θεραπευτικών επιλογών. Η ανάπτυξη ανθεκτικότητας στις καθιερωμένες θεραπείες …

    athens Repository record for Η προκλινική και κλινική ανάπτυξη του Belantamab Mafodotin για τη θεραπεία του Πολλαπλού Μυελώματος/The preclinical and clinical development of Belantamab Mafodotin for the treatment of Multiple Myeloma (opens in a new tab)

  8. The globalization of clinical drug development

    Industry-sponsored clinical research of investigational drugs (also called clinical development) has traditionally been carried out in relatively developed countries in the North American, Western European, and Pacific regions. However, lately it has been widely reported that clinical trials …

    mit Repository record for The globalization of clinical drug development (opens in a new tab)

  9. The effects of licensing and equity financing cycles on pharmaceutical development

    … status, equity issuance cycles, and drug development success at the small pharmaceutical companies that originate these development projects. Specifically, this paper is aimed at identifying how financing alternatives available to small pharmaceutical companies influence development

    mit Repository record for The effects of licensing and equity financing cycles on pharmaceutical development (opens in a new tab)

  10. Essays on Managing Healthcare Ecosystems

    … to pharmaceutical innovation, research and development, and manufacturing and distribution, the healthcare ecosystem is wide ranging in both its functions and stakeholders. This dissertation aims to better understand, evaluate, and address major challenges and inefficiencies in this complex …

    cambridge Repository record for Essays on Managing Healthcare Ecosystems (opens in a new tab)

  11. Are You My Nurse? The Effects of Patient-Delivered Gender Microaggressions on Women Trainees’ Clinical Work in Integrated Primary Care

    … women behavioral health trainees’ during their clinical development by potentially understanding the ways in which women trainees are affected by sexist patient encounters. Therefore, the present study sought to apply the Social Cognitive Model of Counselor Training and the Multicultural …

    denver Repository record for Are You My Nurse? The Effects of Patient-Delivered Gender Microaggressions on Women Trainees’ Clinical Work in Integrated Primary Care (opens in a new tab)

  12. Exploiting a novel organotypic model of SOX2-driven early squamous lung cancer to identify potential routes to chemoprevention

    … using tool compounds and compounds in late phase clinical development for potential efficacy in chemoprevention. I combined this approach with targeted genetic ablation studies to identify/characterise targets that may be key to the progression of SOX2-driven squamous cell carcinomas. In …

    cambridge Repository record for Exploiting a novel organotypic model of SOX2-driven early squamous lung cancer to identify potential routes to chemoprevention (opens in a new tab)

  13. Eluding Antibiotic Resistance: Capitalizing On Antimicrobial Peptides Interaction With The Lipid Bilayer

    … view, with concern, the lack of antibiotics in development, especially those against Gram-negative bacteria.</p> <p>Antimicrobial peptides (AMPs) have been proposed as an alternative to antibiotics due to their selective activity against microbes and minor ability to induce resistance. For …

    uthsc Repository record for Eluding Antibiotic Resistance: Capitalizing On Antimicrobial Peptides Interaction With The Lipid Bilayer (opens in a new tab)

  14. IDENTIFICATION OF AN EFFECTIVE RIBONUCLEOSIDE ANALOGUE AND IMMUNOMODULATORY IMIDE DRUG COMBINATION FOR MULTIPLE MYELOMA

    … MM cells. Collectively, our study offers the preclinical evidence and scientific rationale for further MYC-based biomarker-driven clinical development of nucleotide metabolism/IMiD-based drug combinations against MM.

    nus Repository record for IDENTIFICATION OF AN EFFECTIVE RIBONUCLEOSIDE ANALOGUE AND IMMUNOMODULATORY IMIDE DRUG COMBINATION FOR MULTIPLE MYELOMA (opens in a new tab)

  15. Assessing the impact of tumor evolution on oncology drug development and commercialization

    … indolent hematological malignancy with extensive clinical data available and well-delineated disease phases and response criteria. To represent the rate of diagnosis, patients are "added" to the model every month, and thereafter there is a probability that a patient may either 1) become …

    mit Repository record for Assessing the impact of tumor evolution on oncology drug development and commercialization (opens in a new tab)

  16. Engineering membrane-selective antibiotic peptides to combat multidrug resistance

    … a global health emergency that mandates new drug development strategies. Natural antimicrobial peptides (AMPs) have been long-recognized as a potential source of bacteriolytic drugs, but the shortcomings of non-specific membrane toxicity, proteolytic instability, and in vivo toxicity have stymied …

    mit Repository record for Engineering membrane-selective antibiotic peptides to combat multidrug resistance (opens in a new tab)

  17. Cyclic AMP modulation and its effects on chemo-resistant colon cancer cell proliferation and survival

    … 4 (PDE4) enzymes, which are under clinical development for other disease states, to inhibit the breakdown of cAMP and to assess the effects of raising intracellular cAMP on colon cancer proliferation and survival. I found that some chemo-resistant cancer cells are addicted to …

    glasgow Repository record for Cyclic AMP modulation and its effects on chemo-resistant colon cancer cell proliferation and survival (opens in a new tab)

  18. Determining Mechanisms of Response to Polo-Like Kinase 1 Inhibition In Non-Small Cell Lung Cancer

    … cell lines and inhibitors that were in advanced clinical development. To identify potential biomarkers of response and mechanisms of Plk1 inhibitor-induced apoptosis, we performed an integrated analysis of gene and protein expression, gene mutation, and drug sensitivity using three Plk1 …

    uthsc Repository record for Determining Mechanisms of Response to Polo-Like Kinase 1 Inhibition In Non-Small Cell Lung Cancer (opens in a new tab)

  19. A novel dermaseptin peptide from the defensive skin secretion of Phyllomedusa camba

    … the dermaseptin peptides to be considered for clinical development. Phyllomedusa frog skins and their secretions have been researched in the quest for novel peptides like the dermaseptins, for many years.<br/>In this study, a novel dermaseptin, named DRS-CA-1, was successfully obtained from the …

    qu-belfast Repository record for A novel dermaseptin peptide from the defensive skin secretion of Phyllomedusa camba (opens in a new tab)

Page 1 of 5